Effect of the COVID-19 Pandemic on Radical Prostatectomy: A Turkish Multicenter Study.


Journal

Turkish journal of urology
ISSN: 2149-3235
Titre abrégé: Turk J Urol
Pays: Turkey
ID NLM: 101643563

Informations de publication

Date de publication:
Sep 2022
Historique:
pubmed: 12 8 2022
medline: 12 8 2022
entrez: 11 8 2022
Statut: ppublish

Résumé

The present study examines the effects of the coronavirus disease 2019 pandemic on radical prostatectomy performed as part of localized prostate cancer treatment in Turkey. A retrospective analysis was made of the data of 176 patients from 8 centers in Turkey who underwent radical prostatectomy due to localized prostate cancer over the 2 years spanning March 1, 2019, to February 28, 2021. Within this timeframe, March 1, 2019, to February 28, 2020, was denoted the 1-year pre-coronavirus disease 2019 period, while March 1, 2020, to February 28, 2021, was denoted the 1-year coronavirus disease 2019 period. An analysis was made of whether there was a difference in the number of radical prostatectomies performed for prostate cancer, the time from biopsy to operation, and the biopsy and radical prostatectomy pathology between the 2 periods. It was found that the number of radical prostatectomies performed for localized prostate cancer during the coronavirus disease 2019 pandemic was statistically and highly significantly fewer than in the pre-coronavirus disease 2019 period (P <.001). The patients diagnosed with Gleason 3+3 (low risk) prostate cancer were statistically significantly fewer in number in the coronavirus disease 2019 period (P <.001). The pathological Gleason score was upgrading than the biopsy Gleason score in all patients who underwent in both periods (P <.001). When the periods were compared, the pathological involvement determined by lymph node dissection performed during radical prostatectomy was found to be decreased in the coronavirus disease 2019 period, although the difference was not statistically significant (P =.051). As with many diseases, the diagnosis and treatment of prostate cancer have been adversely affected by the coronavirus disease 2019 pandemic.

Identifiants

pubmed: 35950833
doi: 10.5152/tud.2022.22130
pmc: PMC9623386
doi:

Types de publication

Journal Article

Langues

eng

Pagination

339-345

Références

Future Oncol. 2020 Sep;16(26):1941-1945
pubmed: 32597203
World J Surg Oncol. 2021 Jan 20;19(1):18
pubmed: 33472645
Minerva Urol Nefrol. 2014 Sep;66(3):175-87
pubmed: 24867314
J Urol. 2016 Dec;196(6):1651-1658
pubmed: 27569437
J Urol. 1989 Jul;142(1):66-70
pubmed: 2659826
World J Emerg Surg. 2020 Apr 7;15(1):25
pubmed: 32264898
Cancer Treat Res Commun. 2021;27:100331
pubmed: 33581491
Cochrane Database Syst Rev. 2017 Sep 12;9:CD009625
pubmed: 28895658
Invest Urol. 1979 Sep;17(2):159-63
pubmed: 89106
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Eur Urol. 2020 Jul;78(1):21-28
pubmed: 32376137
Prostate Cancer Prostatic Dis. 2020 Sep;23(3):398-406
pubmed: 32690870
J Urol. 2002 Apr;167(4):1664-9
pubmed: 11912384
Nat Rev Dis Primers. 2021 Feb 4;7(1):9
pubmed: 33542230
Eur Urol. 2020 Jul;78(1):e14-e15
pubmed: 32349936
EClinicalMedicine. 2020 Apr 05;21:100331
pubmed: 32292899
Eur Urol. 2020 Jul;78(1):29-42
pubmed: 32414626
N Engl J Med. 2016 Oct 13;375(15):1415-1424
pubmed: 27626136
Eur Urol. 2020 Apr;77(4):508-547
pubmed: 32001144
Prostate Cancer Prostatic Dis. 2020;23(3):407-409
pubmed: 32425655
Minerva Urol Nefrol. 2017 Oct;69(5):459-465
pubmed: 28008754
Urol Int. 2021;105(1-2):3-16
pubmed: 33227808
Eur Urol. 2013 Aug;64(2):204-15
pubmed: 23453419

Auteurs

Abdullah Gurel (A)

Department of Urology, Afyon Health Sciences University Faculty of Medicine, Afyon, Turkey.

Burhan Baylan (B)

Department of Urology, Afyon Health Sciences University Faculty of Medicine, Afyon, Turkey.

Ibrahim Keles (I)

Department of Urology, Afyon Health Sciences University Faculty of Medicine, Afyon, Turkey.

Arif Demirbas (A)

Department of Urology, Afyon Health Sciences University Faculty of Medicine, Afyon, Turkey.

Mustafa Karalar (M)

Department of Urology, Afyon Health Sciences University Faculty of Medicine, Afyon, Turkey.

Berkay Eren (B)

Department of Urology, Afyon Health Sciences University Faculty of Medicine, Afyon, Turkey.

Ata Ozen (A)

Department of Urology, Eskisehir Osmangazi University Faculty of Medicine, Eskisehir, Turkey.

Unal Oztekin (U)

Department of Urology, Kayseri System Hospital, Kayseri, Turkey.

Can Benlioglu (C)

Department of Urology, Adıyaman University Faculty of Medicine, Adıyaman, Turkey.

Ahmet Emin Dogan (AE)

Health Sciences University, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Urology Clinic, Ankara, Turkey.

Mehmet Altan (M)

Health Sciences University, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Urology Clinic, Ankara, Turkey.

Erol Ersekerci (E)

Department of Urology, Kırşehir Ahi Evran University Faculty of Medicine, Kırşehir, Turkey.

Eren Cengiz (E)

Kayseri City Education and Research Hospital, Kayseri, Turkey.

Mert Ali Karadag (MA)

Kayseri City Education and Research Hospital, Kayseri, Turkey.

Ahmet Yaser Müslümanoğlu (AY)

Department of Urology, Health Sciences University, Bağcılar Training and Research Hospital, İstanbul Turkey.

Classifications MeSH